Optimistic Buy Rating: Strong Phase 2 Results and Regulatory Progress for Verastem's Avutometinib and Defactinib
Cantor Fitzgerald Reiterates Overweight on Verastem
Verastem (VSTM) Receives a Buy From RBC Capital
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $7
Truist Financial Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $15
Verastem Stock: Buy Rating Amid Market Overreaction and Promising Commercial Potential
12 Health Care Stocks Moving In Thursday's Intraday Session
Verastem Advances Cancer Treatment With Promising Trial Results
Verastem Oncology Presents Updated Data On Avutometinib And Defactinib Combo In Recurrent Low-Grade Serous Ovarian Cancer At IGCS 2024
Express News | Verastem Inc - Stock Options Exercise Price Set at $2.82 per Share
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Guggenheim Initiates Verastem(VSTM.US) With Buy Rating, Announces Target Price $13
Verastem Director Brian Stuglik Sells Shares Worth $1,680
Verastem Director Sells Company Shares Worth $803
Verastem CEO Sells Shares Worth $688 to Cover Taxes
Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference
Verastem Oncology To Present Late-breaking Abstract Of The Mature Data From The Ongoing Phase 2 RAMP 201 Clinical Trial At IGCS Annual Meeting
Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024
Outperform Rating and $7 Target for Verastem Amidst LGSOC Treatment Potential and Stock Valuation Opportunity